5-Dimethylaminosulfonyl-2-methoxybenzoic acid chloride | 69046-20-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-Dimethylaminosulfonyl-2-methoxybenzoic acid chloride
• 英文别名: 5-(Dimethylsulfamoyl)-2-methoxybenzoyl chloride
• CAS: 69046-20-4
• 化学式: C₁₀H₁₂ClNO₄S
• 分子量: 277.729
• InChiKey: KFODYSFLGQDJLD-UHFFFAOYSA-N

物化性质

• 沸点：
  419.1±55.0 °C(Predicted)
• 密度：
  1.352±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  aminolupinane 、 5-Dimethylaminosulfonyl-2-methoxybenzoic acid chloride 在 三乙胺 作用下， 以 苯 为溶剂， 反应 1.0h， 以73%的产率得到5-Dimethylsulfamoyl-2-methoxy-N-[(1S,9aR)-1-(octahydro-quinolizin-1-yl)methyl]-benzamide
  参考文献：
  名称：

  Iusco; Boido; Sparatore, Il Farmaco, 1996, vol. 51, # 3, p. 159 - 174

  摘要：

  DOI：
• 作为产物：
  描述：

  5-dimethylsulfamoyl-2-methoxybenzoic acid 在 氯化亚砜 作用下， 反应 1.0h， 生成 5-Dimethylaminosulfonyl-2-methoxybenzoic acid chloride
  参考文献：
  名称：

  Iusco; Boido; Sparatore, Il Farmaco, 1996, vol. 51, # 3, p. 159 - 174

  摘要：

  DOI：

文献信息

• Scavenger assisted combinatorial process for preparing libraries of amides, carbamates and sulfonamides
  申请人：ELI LILLY AND COMPANY

  公开号：EP0825164A2

  公开（公告）日：1998-02-25

  This invention relates to a novel solution phase process for the preparation of amide, carbamate, and sulfonamide combinatorial libraries. These libraries have utility for drug discovery and are used to form wellplate components of novel assay kits.

  这项发明涉及一种用于制备酰胺、碳酸酯和磺酰胺组合库的新型溶液相过程。这些库在药物发现中具有实用价值，并用于形成新型检测套件的微孔板组件。
• Substituted azabicyclo compounds, process for their preparation and pharmaceutical compositions containing them
  申请人：BEECHAM GROUP PLC

  公开号：EP0094742A2

  公开（公告）日：1983-11-23

  A compound of formula (I), or a pharmaceutically acceptable salt, or N-oxide thereof, or a solvate of any of the foregoing: wherein p is 0 to 2; q is 0 to 3; j is 0 to 4; one of R5 and Re is hydrogen, C1-6 alkyl, phenyl or pheny-C1-3 alkyl, which phenyl moietes may be substituted by C1-6 alkyl, C1-6 alkoxy, CF3 or halogen; and the other of R5 and Re is hydrogen or C,.a alkyl; and A is of formula (II): wherein R2, R3 and R4 are each independently selected from hydrogen, halogen, CF3, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-7 acyl, C1-7 carboxylic acylamino, C1-6 alkylsulphonylamino, N-(C1-6alkylsulphonyl)-N-C1-4 alkylamino, C1-6 alkylsulphonyl, C1-6 alkylsulphinyl, hydroxy, nitro or amino, aminocarbonyl, aminosulphonyl, aminosulphonylamino or N-(aminosulphonyl)-C1-4 alkylamino optionally N-substituted by one or two groups selected from C1-6 alkyl, C3-8 cycloalkyl, Cu cycloalkyl C1-4 alkyl, phenyl or phenyl C1-4 alkyl groups or optionally N-disubstituted by C4-5 polymethylene; or any two together are C1-2 alkylenedioxy; j is 0 to 4; and i) R, is independently any one of the values for R2, R3 or R4 except hydrogen or together with R2 is C1-2 alkylenedioxy, C1-2 oxyalkylenethio, C2-3 alkyleneoxy or N-(C1-2 oxyalkylene)-N-C1-6 alkylamino; and one of X is CO and the other is NH; or ii) X is CO and Y is NR16 where R, and R16 together are C1-2 alkylene; or ii) A is of formula (III): wherein: R2, R3 and R4 are as defined in formula (II); G is -N= or -NR13 where R,3 is hydrogen or C1-4 alkyl; L is >C<; E, J and X are each independently -CHR14, -CR14=, -N= or -NR15 where R14 is hydrogen, C1-4 alkyl or C1-4 alkylthio, and R15 is hydrogen or C1-4 alkyl, or one of E, J and Z is C:B where B is 0 or S and the other two are each independently -CR14=, -N= or -NR15 where R14 and R15 are as defined; or E is a bond, one of J and Z is -CHR14=, -N= or -NH15 as defined and the other is -CHR14=, -N=, 0 or S; or iii) A is of formula (IV): wherein: R,, R3 and R4 are as defined in formula (II), except that none is combined with any other variable to form a divalent group; and the nitrogen atom depicted in formula (I) is separated from the nearest nitrogen atom in the moiety A by at least 2 carbon atoms: a process therefor and compositions thereof.

  化合物式（I），或其药学上可接受的盐，或其N-氧化物，或任何上述物质的溶剂化物： 其中p为0至2；q为0至3；j为0至4；R5和Re中的一个为氢，C1-6烷基，苯基或苯基-C1-3烷基，其中苯基基团可以被C1-6烷基，C1-6烷氧基，CF3或卤素取代；另一个为氢或C,.a烷基；而A为式（II）： 其中R2、R3和R4各自独立选择自氢，卤素，CF3，C1-6烷基，C1-6烷氧基，C1-6烷基硫醇，C1-7酰基，C1-7羧酸酰胺，C1-6烷基磺酰胺，N-(C1-6烷基磺酰基)-N-C1-4烷基胺，C1-6烷基磺酰基，C1-6烷基亚磺酰基，羟基，硝基或氨基，氨基羰基，氨基磺酰基，氨基磺酰胺基或N-(氨基磺酰基)-C1-4烷基胺基，可选地N-取代为C1-6烷基，C3-8环烷基，Cu环烷基C1-4烷基，苯基或苯基C1-4烷基基团或可选地N-二取代为C4-5聚亚甲基；或任意两个一起为C1-2烷二氧基；j为0至4；而i）R,是独立的任何一个R2，R3或R4的值，除了氢或与R2一起为C1-2烷二氧基，C1-2氧基烷硫，C2-3烷氧基或N-(C1-2氧基烷基)-N-C1-6烷基胺基；其中一个X为CO，另一个为NH；或ii）X为CO，Y为NR16，其中R,和R16一起为C1-2烷基；或ii）A为式（III）： 其中：R2，R3和R4如式（II）中定义； G为-N=或-NR13，其中R,3为氢或C1-4烷基；L为>C<； E，J和X各自独立为-CHR14，-CR14=，-N=或-NR15，其中R14为氢，C1-4烷基或C1-4烷基硫，而R15为氢或C1-4烷基； 或E，J和Z中的一个为C：B，其中B为0或S，另外两个各自独立为-CR14=，-N=或-NR15，其中R14和R15如定义； 或E为键，其中J和Z中的一个为-CHR14=，-N=或-NH15，如定义，另一个为-CHR14=，-N=，0或S； 或iii）A为式（IV）： 其中：R,, R3和R4如式（II）中定义，但没有组合成二价基团； 而在式（I）中描绘的氮原子与基团A中最近的氮原子之间至少相隔2个碳原子：因此的过程及其组成物。
• Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
  申请人：Amgen Inc.

  公开号：US20030096819A1

  公开（公告）日：2003-05-22

  The present invention comprises a new class of novel aryl and heteroaryl substituted fused pyrrole compounds useful for the prophylaxis and treatment of diseases or conditions, such as TNF-&agr;, IL-1&bgr; , IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of inflammation and other maladies, such as pain and diabetes, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  本发明涉及一类新型的芳基和杂环芳基取代融合吡咯化合物，用于预防和治疗疾病或病症，例如TNF-α，IL-1β，IL-6和/或IL-8介导的疾病，以及其他疾病，如疼痛和糖尿病。特别地，本发明的化合物用于预防和治疗涉及炎症的疾病或病症。因此，本发明还包括包含本发明的化合物的制药组合物，使用本发明的化合物和组合物预防和治疗炎症和其他疾病或病症的方法，以及用于制备本发明化合物的中间体和过程。本发明还涉及制备这种化合物的过程以及在这些过程中有用的中间体。
• Amide derivatives of azabicycloalkanes
  申请人：BEECHAM GROUP PLC

  公开号：EP0115933A2

  公开（公告）日：1984-08-15

  Compounds of formula (I), pharmaceutically acceptable salts, quaternary derivatives and N-oxides thereof, and pharmaceutically acceptable solvates of any of the foregoing: wherein p is 1 to 3; B is C1-7 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1-2 alkyl, or a group (CH2)tR11 where t is 1 or 2 and R11 is thienyl or furyl optionally substituted by one or two substituents selected from C1-6 alkyl, C1-6 alkoxy, trifluoromethyl or halogen, or is phenyl optionally substituted by one or two substituents selected from C1-4 alkoxy, trifluoromethyl, halogen, nitro, carboxy, esterified carboxy, and C1-4 alkyl optionally substituted by hydroxy, C1-4 alkoxy, carboxy, esterified carboxy or in vivo hydrolysable acyloxy; and i) A is a group of formula (II): in which either a) one of X and Y is CO and the other is NH; and R, is selected from halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, and amino optionally substituted by one or two groups selected from C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1-4 alkyl, phenyl and phenyl C1-4 alkyl groups or optionally N,N-disubstituted by C4-5 polymethylene; or X is CO and Y is NR6 where R1 and R6 together are C1-2 alkylene; and either R2, R3 and R4 are each independently selected from the hydrogen, halogen, CF3, C1-6 alkyl, C1-6 alkoxy, C1-6 thio. C1-7 acyl, C1-7 carboxylic acylamino, C1-6 alkyl- amino, N-(C1-6alkyl-sulphonyl)-N-C1 4 alkylamino, alkylsulphonyl, C1-6 alkylsulphinyl, hydroxy, nitro, or aminocarbonyl, aminosclphonyl, aminosulphonyl- N-(aminosulphonyl)-N-C1-4 alkylamino optionally N-substituted by ore or two groups selected from C1-6 alkyl, C3-8 C8-8 cycloalkyl C1-4 alkyl, phenyl and phenyl C1-4 optionally N,N-disubstituted by C4.5 polymethylene; or one of R2, R3 and R4 is selected from the foregoing class and the remaining two of R2, R3 and R4 when on adjacent atoms are together C1-2 alkylenedioxy; or one of X and Y is CO and the other is NH; R1 and R2 together are C1-2 alkylenedioxy or C1-2 oxyalkylenethio, or C2-3 alkyleneoxy in which the oxygen atom is attached to the ring at the 2- position; as depicted in formula (II); and R3 and R4 are each independently selected from the class of values recited hereinbefore for R2, R3 and R4 in paragraph i) a) fereinbefore or when on adjacent atoms are together C1-2 alkylenedioxy; or iii A is a group of formula (III): in which one of X and Y is CO and the other is NH; and R22, R23 and R24 are each independently selected from the class of values of the variables R2, R3 and R4 as defined hereinbefore in paragraph i) a) in relation to formula (II), except C1-2 alkylenedioxy, having useful pharmacological properties, pharmaceutical compositions containing them, a process and intermediates for their preparation, and the use of the compounds.

  式 (I) 化合物、其药学上可接受的盐、季衍生物和 N-氧化物，以及上述任何物质的药学上可接受的溶液： 其中 p 是 1 至 3； B 是 C1-7 烷基、C3-8 环烷基、C3-8 环烷基 C1-2 烷基或基团 (CH2)tR11，其中 t 是 1 或 2，R11 是噻吩基或呋喃基，任选被选自 C1-6 烷基、C1-6 烷氧基、三氟甲基或卤素的一个或两个取代基取代、或苯基，可任选被一个或两个选自 C1-4 烷氧基、三氟甲基、卤素、硝基、羧基、酯化羧基和可任选被羟基、C1-4 烷氧基、羧基、酯化羧基或体内可水解酰氧基取代的 C1-4 烷基的取代基取代；和 i) A 是式 (II) 的基团： 其中 a) X 和 Y 中的一个是 CO，另一个是 NH；以及 R，选自卤素、C1-6 烷基、C1-6 烷氧基、C1-6 硫代烷基和氨基，任选被一个或两个选自 C1-6 烷基、C3-8 环烷基、C3-8 环烷基 C1-4 烷基、苯基和苯基 C1-4 烷基的基团取代，或任选被 C4-5 聚亚甲基 N，N-二取代；或 X 是 CO，Y 是 NR6，其中 R1 和 R6 合在一起是 C1-2 亚烷基；以及 R2、R3 和 R4 各自独立地选自氢、卤素、CF3、C1-6 烷基、C1-6 烷氧基、C1-6 硫代C1-7酰基、C1-7羧基酰氨基、C1-6烷基氨基、N-（C1-6烷基-磺酰基）-N-C1 4烷基氨基、烷基磺酰基、C1-6烷基亚磺酰基、羟基、硝基或氨基羰基、氨基磺酰基、氨磺酰-N-(氨磺酰)-N-C1-4 烷基氨基，可选择被选自 C1-6 烷基、C3-8-C8-8 环烷基、C1-4 烷基、苯基和苯基 C1-4 的矿石基或两个基团 N 取代，可选择被 C4.5 聚亚甲基；或 R2、R3 和 R4 中的一个选自前述类别，R2、R3 和 R4 中的其余两个在相邻原子上共同为 C1-2 亚烷基二氧基；或 X 和 Y 中的一个是 CO，另一个是 NH；R1 和 R2 合在一起是 C1-2 亚烷基二氧基或 C1-2 氧代亚烷基硫代或 C2-3 亚烷氧基，其中氧原子在 2- 位连接到环上；如式 (II) 所示；以及 R3 和 R4 各自独立地选自上文第 i)a)段中为 R2、R3 和 R4 所述的数值类别，或当相邻原子上的 C1-2 亚烷基二氧基在一起时；或 iii A 是式(III)的基团： 其中 X 和 Y 中的一个是 CO，另一个是 NH；以及 R22、R23 和 R24 各自独立地选自上文第 i) a)段定义的与式(II)有关的变量 R2、R3 和 R4 的数值类别，但 C1-2 烷二氧基除外。 这些化合物具有有用的药理特性、含有这些化合物的药物组合物、制备这些化合物的工艺和中间体，以及这些化合物的用途。
• NITROGENOUS MACROCYCLIC COMPOUNDS
  申请人：ISIS PHARMACEUTICALS, INC.

  公开号：EP0817787A1

  公开（公告）日：1998-01-14